rawfin.tv
ImmunityBio Faces Securities Fraud Lawsuit Following FDA Warning, 21% Stock Drop
RegulationstocksAI Generated

ImmunityBio Faces Securities Fraud Lawsuit Following FDA Warning, 21% Stock Drop

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

ImmunityBio, Inc. (IBRX) is facing a securities class action lawsuit initiated by Kahn Swick & Foti, LLC. The lawsuit follows an FDA warning and a subsequent 21% decline in the company's stock price.

ImmunityBioSecurities LawsuitFDA WarningBiotech Stocks

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks